Payment overview · 2025
General Payments
$1,049.97
52 reported records · 15 companies
Healthcare provider profile · identity verified
Jordan Johanson
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · ZEPHYRHILLS, FL · NPI 1487439212
Verified facts
What the public records show
CMS Open Payments records show Jordan Johanson received $1,049.97 in general payments during 2025 across 52 reported records.
Novo Nordisk Inc accounted for 18.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $193.25 | 18.4% | 11 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $189.68 | 18.1% | 11 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $153.93 | 14.7% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $99.61 | 9.5% | 5 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $90.98 | 8.7% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $67.85 | 6.5% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $54.92 | 5.2% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $43.69 | 4.2% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $31.39 | 3.0% | 1 | 2025 |
| Itamar Medical Inc | Unresolved — no canonical attribution shown | $28.22 | 2.7% | 1 | 2025 |
| Renalytix AI, Inc. | Unresolved — no canonical attribution shown | $24.97 | 2.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.28 | 2.0% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $19.25 | 1.8% | 1 | 2025 |
| OPKO Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $15.99 | 1.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.96 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,033.98 | 51 |
| Education | $15.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $130.78 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $105.20 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $102.20 | 4 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $90.98 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $90.31 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $84.48 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $80.39 | 4 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $67.85 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $62.47 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $54.92 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $54.44 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $53.17 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $52.74 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $43.69 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $31.39 | 1 | 2025 |
Source payment records
|
|||||
| WatchPATONE Normalized: watchpatone |
Device | Itamar Medical Inc | $28.22 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $27.65 | 1 | 2025 |
Source payment records
|
|||||
| KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT Normalized: kidneyintelx blood collection convenience kit |
Device | Renalytix AI, Inc. | $24.97 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $19.25 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $19.22 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.22 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.22 | 1 | 2025 |
Source payment records
|
|||||
| RAYALDEE Normalized: rayaldee |
Drug | OPKO Pharmaceuticals, LLC | $15.99 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $11.15 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Methylprednisolone | Methylprednisolone | 207 | 180 |
| Atorvastatin Calcium | Atorvastatin Calcium | 122 | 63 |
| Azithromycin | Azithromycin | 92 | 91 |
| Amlodipine Besylate | Amlodipine Besylate | 90 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 89 | 52 |
| Levothyroxine Sodium | Levothyroxine Sodium | 78 | 38 |
| Losartan Potassium | Losartan Potassium | 72 | 40 |
| Omeprazole | Omeprazole | 68 | 37 |
| Lisinopril | Lisinopril | 64 | 31 |
| Gabapentin | Gabapentin | 60 | 40 |
| Doxycycline Hyclate | Doxycycline Hyclate | 59 | 55 |
| Pantoprazole Sodium | Pantoprazole Sodium | 54 | 38 |
| Simvastatin | Simvastatin | 43 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 40 | 32 |
| Furosemide | Furosemide | 39 | 24 |
| Cephalexin | Cephalexin | 35 | 32 |
| Metformin Hcl | Metformin Hcl | 33 | 16 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 30 | 18 |
| Carvedilol | Carvedilol | 29 | 14 |
| Potassium Chloride | Potassium Chloride | 29 | 19 |
| Glipizide Er | Glipizide | 28 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 28 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Naproxen | Naproxen | 27 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 26 | 13 |
| Meloxicam | Meloxicam | 25 | 22 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 25 | 24 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 24 | 11 |
| Famotidine | Famotidine | 23 | 15 |
| Trazodone Hcl | Trazodone Hcl | 22 | 14 |
| Montelukast Sodium | Montelukast Sodium | 20 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 20 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 19 | 13 |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 18 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 16 |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 17 | suppressed |
| Prednisone | Prednisone | 17 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 14 |
| Tramadol Hcl | Tramadol Hcl | 15 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | 14 |
| Allopurinol | Allopurinol | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Cefdinir | Cefdinir | 12 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Ezetimibe | Ezetimibe | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,049.97 · 52 records | Novo Nordisk Inc | ABRYSVO, ACCRUFER, AIRSUPRA, BREZTRI, COMIRNATY, Cologuard Collection Kit, ELIQUIS, FARXIGA, JARDIANCE, KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT, Kerendia, Korlym, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, RAYALDEE, Rybelsus, VRAYLAR, Veozah, WatchPATONE, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rybelsus play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error